POSTER PRESENTERS

Tip: use Ctrl + F (or Command + F on Mac) to look for a specific speaker

RICK DOBLIN, PhD

Development of MDMA-assisted Psychotherapy for PTSD

Janis Phelps
JANIS PHELPS, PhD

Training Future Psychedelic Therapists

Matthew Johnson
MATTHEW JOHNSON, PhD

Psilocybin-occasioned mystical experiences

BIA LABATE, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

Ben Sessa
BEN SESSA, MD

MDMA-assisted psychotherapy for alcoholism

Michael Mithoefer
MICHAEL MITHOEFER, MD

MDMA-assisted psychotherapy for PTSD: updates & observations

Fernanda Palhano Xavier de Fontes
FERNANDA PALHANO-FONTES, PhD

Findings from a randomized controlled trial with ayahuasca for treatment-resistant depression.

Torsten Passie
TORSTEN PASSIE, MD, PhD

Low-Dose Psycholytic Therapy: A Neglected Approach?

Tania re

TBA

MONNICA WILLIAMS, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

Katrin Preller
KATRIN PRELLER, PhD

Psilocybin induces time-dependent changes in global brain connectivity

Alexander Belser
ALEXANDER BELSER, PhD

Psychedelic Therapy for Gender and Sexual Minorities

Christopher Timmermann
CHRISTOPHER TIMMERMANN, PhD cand

DMT: Neuroscience, phenomenology and therapeutic potential

Elizabeth Nielson
ELIZABETH NIELSON, PhD

Psilocybin-Assisted Treatment of Alcohol Use Disorder

Amanda feilding

 At the Frontier: An Introduction to the Beckley Foundation’s New Psychedelic Research Programme

Wade Davis
WADE DAVIS, PhD

Lessons from a life-time of ethnobotanical research

Francisco Moreno
FRANCISCO MORENO, MD

Psilocybin versus placebo in Treatment Resistant OCD

NEILOUFAR FAMILY, PhD

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Low Dose Lysergic Acid Diethylamide (LSD) in Healthy Volunteers

LEOPARDO YAWA BANE

The uses of Nixi pae in the Huni Kui tradition

Enzo Tagliazucchi
ENZO TAGLIAZUCCHI, PhD

Neural and psychological correlates of inhaled DMT in naturalistic settings

Matthew Jackson
MATTHEW JACKSON

Patient Perspectives from a Psilocybin for Depression Trial

Leor Roseman
LEOR ROSEMAN, PhD

Prophetic-Like Events in Ayahuasca Rituals with Palestinians and Israelis

Jordan Sloshower
JORDAN SLOSHOWER, MD

Psilocybin-assisted therapy of MDD using Acceptance and Commitment Therapy

RosalinD watts, PHD

Panel: Therapeutic Frameworks

Gabby Agin-Liebes
GABBY AGIN-LIEBES, PhD c.

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

Daniela Peluso
DANIELA PELUSO, PhD

The emergence of global ayahuasca

Ido Hartogsohn
IDO HARTOGSOHN, PhD

Psychedelics, Set and setting, Meaning-Enhancement and Placebo Response

RONAN LEVY, JD

Panel: Mainstreaming Psychyedelics

Alan Kooi Davis
ALAN KOOI DAVIS, PhD

Psychedelic-occasioned decreases in trauma among people of color

Mendel Kaelen
MENDEL KAELEN, PhD

Music for/as Psychedelic Therapy

LIANA SANANDA GILLOOLY

Panel: Medicalization of Psychedelics

Ofelia orlanda yolanda mendez altamirano

Curing as a Whole Organism: Mazatec culture

Lucas de Oliveira Maia
LUCAS DE OLIVEIRA MAIA, PhD

Therapeutic effects of ayahuasca by people facing severe physical illness

Emmanuelle A. D. Schindler
EMMANUELLE SCHINDLER, MD, PhD

Effects of Low Oral Dose of Psilocybin in Migraines

Adam Aronovich
ADAM ARONOVICH, PhD cand

Ayahuasca as Relational Medicine

Nadia Hutten
NADIA HUTTEN, PhD cand

Cognitive and subjective effects of LSD in a placebo-controlled study

Malin Uthaug
MALIN UTHAUG, PhD cand

A placebo-controlled study of ayahuasca on mental health in a naturalistic setting

Daan Keiman
DAAN KEIMAN, MA

Integrating Interfaith Spiritual Care Into Psychedelic Therapies and Science

RICARDA EVENS, PhD

The Afterglow Inventory (AGI) – a new instrument to measure subacute effects of the psychedelic experience

Pedram dara

Personal experiences with MDMA-assisted psychotherapy for PTSD

Tobias Buchborn
TOBIAS BUCHBORN, PhD cand

Introduction to the pharmacodynamics of repeated psychedelic-drug intake

Luís Fernando Tófoli
LUIS F. TOFOLI, MD, PhD

An interdisciplinary discussion on the integration of the psychedelic experience

Eric Sienknecht, Psy.D. and Veronika Gold, MFT
ERIC SIENKNECHT, PsyD & VERONIKA GOLD, MFT

Ketamine-Assisted Psychotherapy: Observations

Inti garcÍa flores

Curing as a Whole Organism: Mazatec culture

Michelle Baker Jones
MICHELLE BAKER JONES

Psilocybin treatment for depression – inside perspectives

Henry J Whitfield
HENRY J WHITFIELD, MSc

A longitudinal multiple baseline investigation of psychedelic integration using ACT

Aidan Lyon
AIDAN LYON, PhD

A unified, philosophical account of the mind-revealing effects of psychedelics and meditation

Timo Torsten Schmidt
TIMO TORSTEN SCHMIDT, PhD

fMRI studies of non-pharmacologically induced altered states of consciousness:

Ruben Laukkonen
RUBEN LAUKKONEN, PhD

The phenomenology of truth: How the feeling of insight guides decisions under uncertainty

Eduardo Schenberg
EDUARDO SCHENBERG, PhD

Antes o cérebro não existia (Once, the brain did not exist)

David Nicolas Langlitz
NICOLAS LANGLITZ, PhD

The Paradoxes of Psychedelic Humanities

Natasha L Mason
NATASHA L MASON, PhD cand

Acute effects of psilocybin on glutamate, functional connectivity & subjective state

Olivia Rose Marcus
OLIVIA ROSE MARCUS, PhD c.

Traditionalizing global forms: ethics in vegetalista practices of the Peruvian Amazon

Helle Kaasik
HELLE KAASIK, PhD

Varieties of chemical composition of Ayahuasca.

Balazs Szigeti
BALAZS SZIGETI, PhD

Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology

Raquel bennett, pSY. d

Panel: Clinical Uses of Ketamine

Nicole Amada
NICOLE AMADA

Narrative Self and the Psychedelic Experience: An exploratory qualitative study

Peter Gasser
PETER GASSER, MD

The Development of Psycholytic / Psychedelic Therapy

ANNE WAGNER, PhD

Panel: Therapeutic frameworks

Michiel van elk
MICHIEL VAN ELK, PhD

Effects of Psilocybin Microdosing on Awe and Aesthetic Experiences

Tomas Palenicek
TOMAS PALENICEK, MD, PhD

Expedition Neuron: a journey towards the neurobiology of ayahuasca in a naturalistic setting

Taylor Lyons
TAYLOR LYONS, PhD cand.

The acute and long-term effects of psilocybin in healthy volunteers

Erik davis, PhD

Panel: Mainstreaming Psychedelics

Ido Siemion
IDO SIEMION, PhD

The Hakomi Method in Psychedelic Therapy: Principles and Interventions

Tim Read
TIM READ, MD

The Dark Place: a comprehensive model for psychedelic psychotherapy

David Dupuis
DAVID DUPUIS, PhD

The socialization of hallucinations

Jeffrey Guss
JEFFREY GUSS, MD

Psilocybin-assisted therapy of depressive disorder using ACT as a therapeutic frame

Vincent Verroust
VINCENT VERROUST, PhD cand

The first clinical trials of psilocybin in France (1956-1960)

Simon Ruffell
SIMON RUFFELL, MD

Modulatory Effects of Ayahuasca on Personality Structure in an Adapted Traditional Framework

CAMILLA DAY
CAMILLA DAY, MD

Compassion Experience Scale in Psilocybin for Treatment Resistant Depression

Marc Tuters
MARC TUTERS, PhD

Subcultural Bad Tripping: How Fear, Clarity, Power and Disgust Unite the Cosmic Right Online

J.P. TEN BERGE
JOS TEN BERGE, PhD

Drugs in Art: Instant Inspiration or Placebo?

Anja Katharina Loizaga-Velder
ANJA LOIZAGA-VELDER, PhD

The contribution of indigenous plant medicine traditions to modern psychedelic medicine

Rafael Lancelotta
RAFAEL LANCELOTTA

The Psychotherapeutic Potential of Short-acting Tryptamines

Raphaël Millière
RAPHAËL MILLIÈRE, PhD cand

The Sense of Body Ownership in Drug-Induced States

Livia Goto Silva
LIVIA GOTO SILVA, PhD

Potential therapeutic effects of 5-MeO-DMT in brain insulin resistance

David Luke
DAVID LUKE, PhD

Transpersonal ecodelia: Surveying psychedelically induced biophilia

LUIS FELIPE SEQUEIRA VALÊNCIO
LUIS FELIPE SEQUEIRA VALÊNCIO, PhD

The Role of Research Ethics in the "Psychedelic Renaissance"

NICOLE BUCHANAN, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

Milan Scheidegger
MILAN SCHEIDEGGER, MD, PhD

Pharmahuasca applications for mental health

Jani Pestana
JANI PESTANA, MSc

Motivations & modalities of psychedelic substance use in Reddit's psychonaut community

DAAN OOSTVEEN, PhD

Towards a new materialism in psychedelics studies

Bennet Zelner
BENNET ZELNER, PhD

Panel: Medicalization of Psychedelics

Tehseen noorani, PHD

Panel: Medicalization of Psychedelics

Martin Madsen
MARTIN MADSEN, PhD

Five-hour fMRI mapping after oral psilocybin reveals distinct psilocin-dependent changes in resting state functional connectivity

Elias Dakwar
ELIAS DAKWAR, MD

Ketamine-assisted Treatment of Substance Use Disorders

Hannes Kettner
HANNES KETTNER, MSc

Learning from uncertainty: Relax your priors and trust in the unknown

Richard Zeifman
RICHARD ZEIFMAN, PhD

How Does Psilocybin Therapy Work?: Exploring Experiential Avoidance as a Mechanism of Change

Lynnette A Averill
LYNNETTE AVERILL, PhD

Psychedelic treatments for cognitive impairment, PTSD, depression among veterans

WOUTER J. HANEGRAAFF
WOUTER HANEGRAAFF, PhD

Psychedelics as Rejected Knowledge

Sam Gandy
SAM GANDY, PhD

From Egoism to Ecoism: Psychedelics & Nature Connection

Ingmar Gorman
INGMAR GORMAN, PhD

MDMA-assisted Psychotherapy for PTSD: Beyond Symptom Reduction

Eric vermetten, MD phd

Panels: MDMA for PTSD & Beyond Symptom Reduction

robert Schoevers, phd

Panel: Clinical Uses of Ketamine

Stephen Snelders, phd

Panel: Historical Contexts

Kim Kuypers, phd

Panels: Microdosing II & Multidisciplinary 5-MeO-DMT Research

Emilia sanabria, phd

Panel: Ayahuasca in the lab

Patricia Pisters, phd

Panels: Humanities & Mainstreaming Psychedelics

Rotem petranker, PHD(C)

Microdosing Results from the Global Drug Survey 2019

will hall, Phd (C)

Panel: Medicalization of Psychedelics

Neşe Devenot, Phd

Panel: Mainstreaming Psychedelics

Tijmen Bostoen, MD

Panels: Clinical Uses of Ketamine & Therapeutic Frameworks

flora moujaes, MA

renske eRin blom, Phd cand

Psilocybin in patients with treatment resistant

depression: first clinical experiences from a multicenter RCT

NEWSLETTER

STAY IN TOUCH

Learn about new events and breakthroughs in the psychedelic scientific community.